Drug intelligence / Profile preview

iron hydroxide adipate tartrate

Development stage: Phase 3
Lead developer: Nemysis
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

Iron hydroxide adipate tartrate (IHAT) is a novel oral iron supplement developed as a ferritin mimetic. It consists of a nano-Fe(III) core doped with tartrate salt in an adipate buffer, designed to mimic the structure and absorption profile of dietary ferritin. IHAT is well absorbed in the gut and preserves the gut microbiome compared to traditional iron supplements. Its primary indication is for the treatment of iron deficiency anemia. The drug is being developed by Nemysis and has reached Phase III clinical trials for this indication[1][2][4][5][8].

Brand names: DietoferNutrifer
Other names: nano-Fe(III) ferritin-mimetic

Beyond the preview

Go deeper on iron hydroxide adipate tartrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iron hydroxide adipate tartrate.

Explore the full profile